
GW Pharmaceuticals hires chief operating officer
pharmafile | October 4, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Chris Tovey, GW Pharmaceuticals
GW Pharmaceuticals has announced the appointment of Christopher John Tovey to the newly created position of chief operating officer.
Tovey, 47, joins GW having gained a wealth of commercial experience from more than 25 years in the pharmaceutical industry. He was most recently vice president Global Marketing Operations at UCB Pharmaceuticals.
Prior to joining UCB Tovey was vice president managing director UK & Ireland at Nabi Biopharmaceuticals, a US based biopharmaceutical company. Before joining Nabi, he spent 18 years at GlaxoSmithKline, in senior commercial roles in both the European and UK organisations.
Dr Geoffrey Guy, chairman, said: “We are pleased to welcome Chris Tovey to GW. With multiple recent launches of Sativex, numerous additional launches planned, and major advances in our pipeline, GW’s operations have now expanded significantly. We are delighted to have attracted in Chris someone with extensive and diverse commercial experience across the pharmaceutical industry to perform the important role of chief operating officer.”
Tovey added: “I am delighted to be joining GW at such an important time in the company’s history. My experience of managing commercial operations across a large number of therapeutic areas in most major markets of the world will, I believe, be of value to GW as it continues its transformation into a commercial company with a rich pipeline.”
Related Content

Cannabidiol drug found to aid in devastating childhood epilepsy condition
A treatment derived from cannabis has been found to produce remarkable results in children who …

GW Pharma releases positive data on cannabidiol-based Phase III trial
GW Pharmaceuticals’ Epidiolex is designed to treat seizures in a rare form of epilepsy called …

Weekly Movers: CytRx, Coherus BioSciences, Juno Therapeutics…
Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing …






